References
- Heaney ML, Golde DW. Myelodysplasia. N Engl J Med 1999;340:1649–1660.
- Lowenthal RM, Marsden KA. Myelodysplastic syndromes. Int J Hematol 1997;5:319–338.
- Jädersten M, Hellström-Lindberg E. Myelodysplastic syndromes: biology and treatment. J Intern Med 2009;265:307–328.
- Tamaki H, Ogawa H, Ohyashiki K, et al. The Wilms’ tumor gene is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 1999;13:393–399.
- Patmasiriwat P, Fraizer G, Kantarjian H, et al. WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia. Leukemia 1999;13:891–900.
- Elisseeva OA, Oka Y, Tsuboi A, et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002;99:3272–3297.
- Cilloni D, Gottardi E, Messa F, et al. Significant correlation between the degree of WT1 expression and the international prognostic scoring system score in patients with myelodysplastic syndromes. J Clin Oncol 2003;21:1988–1995.
- Cilloni D. Is WT1 helping the molecular monitoring of minimal residual disease to get easier in acute myeloid leukaemia?Leuk Res 2009;33:1276–1281.
- Ikeda H, Lethe B, Lehmann F, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997;6:199–208.
- Matsushita M, Ikeda H, Kizaki M, et al. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br J Haematol 2001;112:916–926.
- Steinbach D, Hermann J, Viehmann S, et al. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet 2002;133:118–123.
- Greiner J, Ringhoffer M, Taniguchi M, et al. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer 2004;108:704–711.
- Paydas S, Tanriverdi K, Yavuz S, et al. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects. Am J Hematol 2005;79:257–261.
- Qin Y, Zhu H, Jiang B, et al. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease. Leuk Res 2009;33:384–390.
- Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–2088.
- Qian J, Zhu ZH, Lin J, et al. Hypomethylation of PRAME promoter is associated with poor prognosis in myelodysplastic syndrome. Br J Haematol 2011;154:153–155.
- Li X, Wu L, Ying S, et al. Wilms’ tumor gene (WT1) is predominantly expressed in clonal hematopoietic cells in myelodysplastic syndromes. Leuk Lymphoma 2007;48:601–604.
- van Dijk JP, Knops GH, van De Locht LT, et al. Abnormal WT1 expression in the CD34-negative compartment in myelodysplastic bone marrow. Br J Haematol 2002;118:1027–1033.
- Wertheim GB, Bagg A. Minimal residual disease testing to predict relapse following transplant for AML and high-grade myelodysplastic syndromes. Expert Rev Mol Diagn 2011;11:361–366.
- DiNardo CD, Luger SM. Beyond morphology: minimal residual disease detection in acute myeloid leukemia. Curr Opin Hematol 2012;19:82–88.
- Garcés-Eisele J. Molecular biology strategies to detect residual disease. Hematology 2012;17(Suppl. 1):66–68.
- Cilloni D, Messa F, Arruga F, et al. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica 2008;93:921–924.
- Candoni A, Tiribelli M, Toffoletti E, et al. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Eur J Haematol 2009;82:61–68.
- Kröger N, Bacher U, Bader P, et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant 2010;16:1187–1211.
- Oran B, Giralt S, Couriel D, et al. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 2007;21: 2540–2544.